Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors

Nominees for election by shareholders at Annual General Meeting (AGM) in February 2016

Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms. Elizabeth Doherty and Mr. Ton Buechner for election to the Board at the Annual General Meeting (AGM) of Shareholders to be held on February 23, 2016.

Ms. Doherty is a finance professional with a career spanning more than 35 years in the fast moving consumer goods industry where she developed strategies and programs to improve business outcomes and drive shareholder value. Ms. Doherty is a British national and seasoned professional having served as a CFO and member of the Board of Directors on numerous corporations.

Mr. Buechner is the CEO and Chairman of the Executive Board of AkzoNobel, a Dutch multinational active in the fields of decorative paints, performance coatings and specialty chemicals. As a business leader and engineer by training, Mr. Buechner has successfully led global companies with portfolios targeting both business to business and direct to consumer activities.

Disclaimer
The foregoing release contains forward-looking statements that can be identified by words such as "nominating," "to be held," or similar terms, or by express or implied discussions regarding the potential that Ms. Doherty and Mr. Buechner will be elected to the Board of Directors and of the potential impact of election on Novartis. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Ms. Doherty or Mr. Buechner will be elected to the Board of Directors, or that their election will have any particular impact on Novartis. In particular, management's expectations could be affected by, among other things, the uncertainties inherent in research and development, including unexpected research or clinical trial results and additional analysis of existing data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.

 

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

 

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.